Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Therapeutics Acquisition stock | $10.32

Learn how to easily invest in Therapeutics Acquisition stock.

Therapeutics Acquisition Corp is a shell companies business based in the US. Therapeutics Acquisition shares (RACA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Therapeutics Acquisition

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RACA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Therapeutics Acquisition stock price (NASDAQ: RACA)

Use our graph to track the performance of RACA stocks over time.

Therapeutics Acquisition shares at a glance

Information last updated 2021-07-28.
Latest market close$10.32
52-week range$9.81 - $17.00
50-day moving average $10.24
200-day moving average $11.99
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Therapeutics Acquisition shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Therapeutics Acquisition stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Therapeutics Acquisition price performance over time

Historical closes compared with the close of $10.32 from 2021-05-28

1 week (2021-07-25) N/A
1 month (2021-07-02) 16.09%
3 months (2021-05-05) 3.10%
6 months (2021-02-01) N/A
1 year (2020-08-01) N/A
2 years (2019-08-01) N/A
3 years (2018-08-01) N/A
5 years (2016-08-01) N/A

Therapeutics Acquisition financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM -9999999%
Profit margin 0%
Book value N/A
Market capitalisation $179.1 million

TTM: trailing 12 months

Shorting Therapeutics Acquisition shares

There are currently 366,071 Therapeutics Acquisition shares held short by investors – that's known as Therapeutics Acquisition's "short interest". This figure is 0.8% down from 368,894 last month.

There are a few different ways that this level of interest in shorting Therapeutics Acquisition shares can be evaluated.

Therapeutics Acquisition's "short interest ratio" (SIR)

Therapeutics Acquisition's "short interest ratio" (SIR) is the quantity of Therapeutics Acquisition shares currently shorted divided by the average quantity of Therapeutics Acquisition shares traded daily (recently around 10914.460345856). Therapeutics Acquisition's SIR currently stands at 33.54. In other words for every 100,000 Therapeutics Acquisition shares traded daily on the market, roughly 33540 shares are currently held short.

However Therapeutics Acquisition's short interest can also be evaluated against the total number of Therapeutics Acquisition shares, or, against the total number of tradable Therapeutics Acquisition shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Therapeutics Acquisition's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Therapeutics Acquisition shares in existence, roughly 20 shares are currently held short) or 0.0562% of the tradable shares (for every 100,000 tradable Therapeutics Acquisition shares, roughly 56 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Therapeutics Acquisition.

Find out more about how you can short Therapeutics Acquisition stock.

Therapeutics Acquisition share dividends

We're not expecting Therapeutics Acquisition to pay a dividend over the next 12 months.

Therapeutics Acquisition overview

Therapeutics Acquisition Corp. , doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts. .

Therapeutics Acquisition in the news

There are no recent company news

Frequently asked questions

What percentage of Therapeutics Acquisition is owned by institutions?
Currently 107.6% of Therapeutics Acquisition shares are held by institutions.
When does the fiscal year end for Therapeutics Acquisition?
Therapeutics Acquisition's fiscal year ends in December.
Where is Therapeutics Acquisition based?
Therapeutics Acquisition's address is: 200 Berkeley Street, Boston, MA, United States, 02116
What is Therapeutics Acquisition's ISIN number?
Therapeutics Acquisition's international securities identification number is: US88339T1034

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site